Immunotherapy for Hematologic Malignancies

Dear Colleagues,

Hematological malignancies present some unique challenges like disease heterogeneity, drug resistance leading to relapse and persistence of minimal residual disease, and the emergent immunosuppressive microenvironment resulting in sanctuary sites within the bone marrow.  The introduction of immunotherapy either in the form of immunomodulators, checkpoint inhibitors, immune cell engagers like bispecific T cell engagers (BiTEs), or Chimeric Antigen Receptor (CAR)-T cell therapy has heralded a new era in combating hematological malignancy.

The present issue will focus on studies trying to delineate the process of emergence of the immunosuppressive environment and the advancements made in immune therapy to overcome this hurdle.  The emphasis will be on capturing the different approaches utilized to increase the immune-based tools available to improve patient outcomes in hematological malignancy.  Areas of interest will include multitargeted approaches in overcoming immune evasion, tumor vaccination, and preventive measures utilized to decrease toxicity, especially immune-related adverse effects. 

Dr. Rajesh Ramakrishnan Nair
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.